Diseases of the Esophagus (2014) 27, 802 DOI: 10.1111/dote.12018
Retraction
Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma
This article has been retracted at the request of Editors-in-Chief André Duranceau and John Pandolfino. Retraction: The following article from Diseases of the Esophagus, ‘Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma’ by X. F. Guo, X. F. Zhu, G. S. Zhong, and B. G. Deng, published online on 27 March 2012 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editors-in-Chief, André Duranceau and John Pandolfino, and Wiley Periodicals, Inc. The retraction has been agreed due to overlap with previously published material in: Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H. ‘Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.’ Oncol Rep 2012; 27: 1639–1645. Reference Guo, X. F., Zhu, X. F., Zhong, G. S. and Deng, B. G. (2012), ‘Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.’ Diseases of the Esophagus. doi: 10.1111/j.1442-2050.2012.01332.x
802
© 2012 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
Copyright of Diseases of the Esophagus is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.